Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's AI-driven ...

Eli Lilly (LLY) recently collaborated with Superluminal Medicines to advance therapeutics targeting cardiometabolic diseases, ...

(Reuters) -Superluminal Medicines said on Thursday it had signed a deal with U.S. drugmaker Eli Lilly worth up to $1.3 ...

Having backed Superluminal Medicines’ series A last year, Eli Lilly has now signed a $1.3 billion pact with the G ...

In a move poised to shake the pharmaceutical landscape, Eli Lilly & Co. has inked a deal worth up to $1.3 billion with ...

Eli Lilly will pay up to $1.3bn for Superluminal Medicines to discover and progress small-molecule therapeutics for G protein ...

Eli Lilly (LLY) has entered into a deal worth up to $1.3 billion with drug discovery company Superluminal Medicines to ...

The Boston-based AI/ML startup focuses on endocrine and cardiometabolic diseases and will use that expertise to generate new ...

On the other hand, I would be delighted by robust experimental results on superluminal (or lack of) group velocities, and I hope they are planning a follow-up paper.

Today, I am pleased to be able to give an example of superluminal experiments done right. In work published in Physical Review A, a group of researchers from NIST and the Wuhan Institute of ...